about
Mu-opioid antagonists for opioid-induced bowel dysfunctionTreatment of opioid-induced gut dysfunctionVgamma9Vdelta2 T cell-mediated recognition of human solid tumors. Potential for immunotherapy of hepatocellular and colorectal carcinomas.Managing opioid-induced constipation in advanced illness: focus on methylnaltrexone bromide.Methylnaltrexone: the evidence for its use in the management of opioid-induced constipation.Prophylactic use of laxative for constipation in critically ill patientsAnesthetic Routines: The Anesthesiologist's Role in GI Recovery and Postoperative IleusOpioids and the gut: pharmacology and current clinical experience.Methylnaltrexone, a novel peripheral opioid receptor antagonist for the treatment of opioid side effects.A review of methylnaltrexone, a peripheral opioid receptor antagonist, and its role in opioid-induced constipation.Novel opioid antagonists for opioid-induced bowel dysfunction and postoperative ileus.Preferential Delivery of an Opioid Antagonist to the Fetal Brain in Pregnant MiceNew treatments for irritable bowel syndrome in womenEmerging drugs for chronic constipation.Methylnaltrexone bromide: research update of pharmacokinetics following parenteral administration.Use of methylnaltrexone to induce laxation in acutely injured patients with burns and necrotizing soft-tissue infections.The effect of methylnaltrexone on the side effects of intrathecal morphine after orthopedic surgery under spinal anesthesia.Bioavailability of oral methylnaltrexone increases with a phosphatidylcholine-based formulation.Opioid-induced constipation in intensive care patients: relief in sight?Naloxone treatment for irritable bowel syndrome--a randomized controlled trial with an oral formulation.Tolerability, gut effects, and pharmacokinetics of methylnaltrexone following repeated intravenous administration in humans.Formulary Drug Review: Naldemedine.
P2860
Q24243268-0DC80185-ABDB-4ED3-B1FF-552620F15145Q28284578-9252965B-86CB-4E09-AFDB-67194AE38615Q33296232-405C5C81-F154-41D4-BB67-B98E9A71CD22Q33715430-75926EA7-DB12-4FB0-A84C-A66447DCF8D1Q33973870-B72A51C4-4013-4996-B2CF-A4A713C7FB08Q34195940-C0F91FBC-BA9D-480A-8DDC-77C706B87F22Q35202119-92CAAE28-E55D-445E-A444-8C559F923E2EQ35860904-97667339-EEDD-4B51-B737-03378F0DDA18Q36458384-EA5485D0-7E6F-4AFC-9AEE-3B3F4DDCD0CDQ36852958-F9B8D026-D9BB-482F-919B-83B2D28D8AE1Q36936210-A16049F5-736B-40C2-AB4E-C9BF39270918Q37062561-76AAB7E8-ABF4-4206-9DB8-BD0AD1D2D24AQ37120300-A18A2330-8DAE-4BE0-A7A0-F7517B4D6217Q37570550-1CF78D70-FFE4-4460-A415-5CED45142808Q37827493-7620D016-05EC-49AB-B502-5844CA6C2853Q38123353-A5EDD352-00AD-411E-8FD5-E60B8D84F053Q39211193-FEAF2EAB-E765-4911-8B99-993D7FDADC66Q39234260-503B3A39-54AB-4538-92B2-B6A8730B3059Q39317602-AAA35751-BB30-45E0-AB4D-07720C0397EEQ39403721-E9F74650-C01C-4CA2-AC4B-2B57E93A9588Q46438870-B0A4A53C-166E-4E0A-BCB4-E0C8B53770E5Q49587086-54B28A86-FD88-4417-BAB3-C6D8452EC31B
P2860
description
2000 nî lūn-bûn
@nan
2000 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Oral methylnaltrexone for opioid-induced constipation
@ast
Oral methylnaltrexone for opioid-induced constipation
@en
Oral methylnaltrexone for opioid-induced constipation
@nl
type
label
Oral methylnaltrexone for opioid-induced constipation
@ast
Oral methylnaltrexone for opioid-induced constipation
@en
Oral methylnaltrexone for opioid-induced constipation
@nl
prefLabel
Oral methylnaltrexone for opioid-induced constipation
@ast
Oral methylnaltrexone for opioid-induced constipation
@en
Oral methylnaltrexone for opioid-induced constipation
@nl
P356
P1476
Oral methylnaltrexone for opioid-induced constipation
@en
P2093
P304
P356
10.1001/JAMA.284.11.1383
P407
P577
2000-09-20T00:00:00Z